BRCA1 and breast carcinoma: BRCA1 deficient cells are highly sensitive to PARP and DNA methyltransferase inhibition in comparison with wild-type BRCA1 cells, resulting in clinical trials in breast cancer patients to test the efficiency of these drugs (Dobrovic and Simpfendorfer, 1997).